Analysts Set Proteon Therapeutics, Inc. (PRTO) Price Target at $3.50
Proteon Therapeutics, Inc. (NASDAQ:PRTO) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $3.50.
PRTO has been the topic of a number of recent research reports. Oppenheimer Holdings, Inc. reaffirmed a “market perform” rating on shares of Proteon Therapeutics in a research report on Wednesday, August 16th. HC Wainwright set a $2.00 target price on shares of Proteon Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Cowen and Company reaffirmed a “hold” rating on shares of Proteon Therapeutics in a research report on Tuesday, August 8th. Finally, Zacks Investment Research downgraded shares of Proteon Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th.
Shares of Proteon Therapeutics (PRTO) traded down 1.852% on Tuesday, hitting $1.325. 40,796 shares of the stock were exchanged. The company’s market cap is $23.35 million. The company has a 50-day moving average price of $1.33 and a 200 day moving average price of $1.46. Proteon Therapeutics has a 12 month low of $1.10 and a 12 month high of $11.45.
Proteon Therapeutics (NASDAQ:PRTO) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.11. Equities analysts forecast that Proteon Therapeutics will post ($1.52) EPS for the current fiscal year.
A hedge fund recently bought a new stake in Proteon Therapeutics stock. RA Capital Management LLC acquired a new stake in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics comprises about 0.2% of RA Capital Management LLC’s investment portfolio, making the stock its 22nd biggest position. RA Capital Management LLC owned about 7.59% of Proteon Therapeutics at the end of the most recent reporting period. Institutional investors own 47.16% of the company’s stock.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Stock Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related stocks with our FREE daily email newsletter.